João Igor Dantas Landim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
João Igor Dantas Landim has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Braga Cruz Guedes de Morais
Hospital Geral de Fortaleza, Departamento de Neurologia, Fortaleza CE, Brazil
1 shared publication - Amanda Vale Catunda
Hospital Geral de Fortaleza, Departamento de Neurologia, Fortaleza CE, Brazil
1 shared publication - Ana Silvia Sobreira Lima Verde
Movement Disorders Division, Department of Neurology Hospital Geral de Fortaleza Fortaleza Brazil
1 shared publication - Bruno Diógenes Iepsen
Hospital Geral de Fortaleza
1 shared publication - Ian Silva Ribeiro
Hospital Geral de Fortaleza, Departamento de Neurologia, Fortaleza CE, Brazil
1 shared publication - Norberto Anízio Ferreira Frota
Hospital Geral de Fortaleza
1 shared publication
Latest Publications
- Open Access
- 15 July 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (12) , 001-006
Cerebrospinal fluid biomarkers in cerebral amyloid angiopathy: insights from a clinical case series
Cerebral amyloid angiopathy (CAA) is a small vessel disease characterized by the deposition of amyloid-beta in small cerebral vessels, which can lead to intracerebral hemorrhages and cognitive impairment. Rare variants, such as cerebral amyloid angiopathy-related inflammation (CAA-ri) and iatrogenic CAA (ICAA), may mimic other neurological conditions and challenge diagnosis in clinical practice. We present three cases that illustrate distinct CAA syndromes, along with CSF biomarker analysis. One patient experienced recurrent hemorrhagic strokes with a history of dural graft, raising concerns about amyloid transmission. Two patients presented with rapidly progressive dementia that fulfilled CAA-ri criteria. All cases exhibited decreased levels of CSF Aβ40 and Aβ42, with one showing elevated p-tau, suggesting comorbid Alzheimer's pathology. Cerebrospinal fluid biomarkers complement neuroimaging in the diagnosis of CAA, aiding in differentiation from other dementias. Early recognition and diagnosis of CAA-ri variants is crucial, because immunotherapy may improve outcomes. Further research is necessary to establish biomarker thresholds and their clinical applicability.
- 15 July 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (12) , 001-006
Open AccessCerebrospinal fluid biomarkers in cerebral amyloid angiopathy: insights from a clinical case series
Cerebral amyloid angiopathy (CAA) is a small vessel disease characterized by the deposition of amyloid-beta in small cerebral vessels, which can lead to intracerebral hemorrhages and cognitive impairment. Rare variants, such as cerebral amyloid angiopathy-related inflammation (CAA-ri) and iatrogenic CAA (ICAA), may mimic other neurological conditions and challenge diagnosis in clinical practice. We present three cases that illustrate distinct CAA syndromes, along with CSF biomarker analysis. One patient experienced recurrent hemorrhagic strokes with a history of dural graft, raising concerns about amyloid transmission. Two patients presented with rapidly progressive dementia that fulfilled CAA-ri criteria. All cases exhibited decreased levels of CSF Aβ40 and Aβ42, with one showing elevated p-tau, suggesting comorbid Alzheimer's pathology. Cerebrospinal fluid biomarkers complement neuroimaging in the diagnosis of CAA, aiding in differentiation from other dementias. Early recognition and diagnosis of CAA-ri variants is crucial, because immunotherapy may improve outcomes. Further research is necessary to establish biomarker thresholds and their clinical applicability.